Delta flight returns to Atlanta after pressurization issue
The Brief
Delta Flight 1457 returned to Atlanta due to a pressurization issue, ensuring passenger safety.
The aircraft landed safely and taxied to the gate under its own power.
The cause of the mechanical issue is still under investigation.
ATLANTA - A Delta Air Lines flight en route to Tampa returned to Atlanta Friday after the crew reported a mechanical issue during the flight, the airline said.
What we know
Delta Flight 1457, a Boeing 757 carrying 193 passengers, two pilots, and four flight attendants, turned back to Hartsfield-Jackson Atlanta International Airport due to a pressurization issue, according to a statement from the company.
The aircraft landed safely and taxied to the gate under its own power.
What they're saying
"Nothing is more important than the safety of our customers and people," a Delta spokesperson said. "That is why the flight crew of Delta flight 1457 followed established procedures and returned to Atlanta after a mechanical issue was observed during flight. We apologize to our customers for the delay in their travel."
What we don't know
The cause remains under investigation.
What's next
The plane took off shortly after 11 p.m., according to Fligthaware.com and is expected to land after midnight on Saturday.
The Source
The details in this article were provided by Delta Air Lines with additional flight information provided by Flight Aware.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
25 minutes ago
- Forbes
Employers Reluctant To Cover Obesity Meds, Lower Costs May Change This
A new survey report from the International Foundation of Employee Benefit Plans shows continued reluctance by United States employers to cover glucagon-like peptide-1 drugs for weight loss. Going forward, however, lower net costs may induce better coverage by employers. Makers of GLP-1s for obesity are offering an array of discounts, some to insurers, others directly to patients. The IFEBP first conducted the survey in Oct. 2023 and again in May 2024. In the latest survey released ten days ago, employers revealed that 55% of them provide coverage of GLP-1s for diabetes only, while only 36% provide coverage for both diabetes and weight loss. And of those employers currently offering GLP-1 drug coverage solely for diabetes, just 17% are considering reimbursement of drugs for weight loss. Broadly speaking, the survey responses demonstrate that a large number of employers are still unwilling to reimburse GLP-1s for obesity. The weight loss therapeutics activate the body's receptors for GLP-1 on its own or in combination with GIP. When released by the gut, these natural hormones increase insulin delivery, suppress appetite, slow stomach emptying and increase the feeling of fullness. Perhaps what's driving continued reluctance to cover these products for weight loss is the overall impact that GLP-1s have on employers' pharmacy budgets. GLP-1 drugs used for obesity account for an average of 10.5% of total annual claims in the 2025 survey. In parts of the traditional health plans' market, we observe that some insurers are reconsidering their coverage of GLP-1s. Blue Cross Blue Shield, for example, just announced a reversal in its policy in which some plans offered coverage of GLP-1s for obesity. Starting in January 2026, BCBS will no longer cover these medicines for weight loss across the insurer's standard plans. At the same time, however, the large insurer Cigna announced it will begin capping out-of-pocket costs at $200 per month, starting next month, for patients using the obesity drugs Wegovy (semaglutide) and Zepbound (tirzepatide) through an add-on to its pharmacy benefit management plans. This is aimed at encouraging more employers to offer coverage of the drugs. It's unknown what the net cost to Cigna will be for the medicines. But presumably, the insurer has been able to reach a deal that's favorable financially, meaning a substantial reduction in net costs. It's possible in future that employers decide to revisit their coverage decisions if net costs decrease sufficiently, combined with more data showing the benefits of weight loss drugs when taken consistently and in conjunction with an appropriate dietary and exercise regimen. Also, the pharmaceutical firm Novo Nordisk announced last month a new partnership with CVS Caremark, the nation's largest pharmacy benefit manager, which grants coverage of Wegovy over its competitor Zepbound for customers who are insured for obesity medications. It's presumed that CVS was able to negotiate sizable rebates for Wegovy. CVS Caremark said that for insured patients, starting this July, Wegovy and Saxenda (liraglutide) will be the preferred GLP-1 medicines on its largest commercial formularies. This implies fewer access restrictions such as prior authorization, but also lower patient cost-sharing. It's unknown precisely what this means in terms of out-of-pocket costs for patients. But most patients with coverage for obesity drugs have monthly cost-sharing under $100. The arrangements reached by Cigna and CVS could help bring down net prices for employers for popular weight loss medicines. And at the same time, under the Inflation Reduction Act, the federal government is negotiating the prices of the GLP-1s Ozempic (semaglutide) and Wegovy. So-called maximum fair prices will be publicly posted in early 2026. These could reflect even steeper discounts. In addition to what payers are doing, Novo Nordisk is pursuing a direct-to-patient strategy to regain market share it has lost to drug maker Eli Lilly in the lucrative obesity drug market. Here, Novo Nordisk struck a deal in which CVS pharmacy will offer Wegovy for $499 a month for cash-paying customers who aren't insured for the medication. Since the Food and Drug Administration removed the active ingredients semaglutide and tirzepatide from its shortage list, the business model of selling directly at a considerable discount to the consumer has become popular for the two main manufacturers of obesity drugs. In 2024, Eli Lilly adopted a direct-to-consumer strategy for Zepbound, among other products, with its LillyDirect program. This service includes a DTC pharmacy and a referral network of in-person and telehealth clinicians. LillyDirect allows uninsured or underinsured individuals not on Medicaid or Medicare to purchase Zepbound product directly after obtaining the requisite prescription from their doctor. The firm recently extended the range of Zepbound products available through LillyDirect by adding high-dose vials at $499. Rival Novo Nordisk also launched a DTC option, NovoCare Pharmacy, two months ago. Patients not insured in the public sector who wish to have access to Wegovy can acquire the drug for an out-of-pocket cost of $499 per month, provided they have a prescription and make use of a designated specialty pharmacy. And, since the end of April, customers also pay a $499 monthly subscription when they obtain Wegovy from Ro and LifeMD, and $599 at Hims & Hers. While employers aren't yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future coverage decisions.
E&E News
26 minutes ago
- E&E News
Meet the youth challenging Trump on climate
Eva Lighthiser, 19, lives in Livingston, Montana, and is accustomed to milelong coal trains rumbling through town and blowing coal dust across the city. In 2023, she was a plaintiff in a youth-led lawsuit that sought to force her state to tackle climate change. Now, she's the lead challenger in Lighthiser v. Trump, a new climate lawsuit that accuses President Donald Trump of violating the Constitution by issuing a trio of executive orders that fast track fossil fuel development. 'Every place is going to be affected by this administration and it's very concerning to see what that will look like moving forward,' Lighthiser said in an interview. Advertisement The case, filed last week in the U.S. District Court for the District of Montana, argues that Trump's executive orders will worsen climate change and increase health dangers by declaring a 'national energy emergency' and directing the government to 'unleash American energy.'
Travel Weekly
26 minutes ago
- Travel Weekly
ASTA's Zane Kerby addresses key issues for travel advisors
ASTA CEO Zane Kerby sat down with tours and river cruise editor Brinley Hineman at the Society's Salt Lake City conference last month, where they discussed AI and the impact it will have on travel advisors, the organization's key priorities for advocacy efforts and how members' businesses are faring amid an uncertain economy. Zane Kerby Q: What are some key advocacy efforts underway? A: We have really important touchpoints with the Department of Transportation and with Congress to try to get our members from under this onerous provision [about merchant of record refunds] that was written into the FAA [reauthorization bill]. It doesn't affect a whole lot of our members, but for the ones that it affects, it is extraordinarily dangerous, so we want that fixed immediately. We also have written to DOT secretary [Sean] Duffy, who reached out to groups like ASTA to ask them which regulations were no longer in the public's interest. Q: How is AI impacting things for members? A: I talked to the ASTA board about this the other day, and I feel like I'm the most concerned about it of any of the 15 advisors that sit on our board. They're still looking at it as a really good research assistant. The reason that our profession is sturdy is because of the trust that exists between consumers and travel advisors. I'm not sure that AI is going to supplant that trust with a bunch of haphazard recommendations. It doesn't feel to me like it's replacing the trust at all that exists between consumers and travel advisors. Q: There's a lot going on, with economic uncertainty and with the U.S. projected to lose $12.5 billion in inbound travel. What's on your mind? A: I'm really thankful that my job is not inbound tourism to the United States. The vast majority of our members are executing and planning trips that are outbound from the United States, and that business is very, very good. We certainly understand that public policy decisions that affect Americans' willingness to travel abroad is important to keep our eye on. As we have talked to our members, both here and in surveys beforehand and anecdotally over the last several months, so far -- touch wood -- business is going very, very well for members. Obviously, it's something we want to keep an eye on, and we try to be proactive. But it's certainly not helpful to opine on every public policy decision that's made. When public policy decisions that are made affect our members' businesses, we will react and act appropriately at the time. Q: So it's not affecting advisors planning outbound travel? A: That's largely the case. Now, there are pockets: We're in the D.C. area, and so when I talk to advisors in the D.C. area, on the luxury side, everything is going gangbusters. But for those who are affected -- there's a large federal workforce in the D.C. area, and so some of that uncertainty [that comes] with layoffs and proposed layoffs has affected some travel in that sort of midtier range. Q: What about members planning domestic travel? A: Members are getting a lot of questions around the national parks this year, for obvious reasons. I think that it is having some effect, but it's not [having a big impact]. Even the domestic business is good -- pockets of stress, but nothing I'm worried about.
